G-CSF plus plerixafor was more effective for first-line mobilization than G-CSF alone in MM and NHL patients [113] and also proved effective in patients with Hodgkin's lymphoma (HL) [114, 115]. This evidence concerns the gene CSF3 and non-Hodgkin lymphoma.